This occurs because the ERK pathway degrades FBXW7 in a phosphorylation-dependent manner, and pancreatic cancer cells with defective FBXW7 phosphorylation sites exhibit oncogenic resistance to ERK pathway activation (Ji et al., 2015). This evidence concerns the gene FBXW7 and pancreatic neoplasm.